跳至主要内容
临床试验/NCT05364606
NCT05364606招募中不适用

Patient Specific Talus Spacer Post Approval Study

Paragon 286 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年7月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Paragon 28
入组人数
50
试验地点
6
主要终点
A lack Secondary Subsequent Surgical Intervention at 5 years Post Operative assessed during the subject's visits

研究概览

简要总结

Humanitarian Device Exemption Approved Patient Specific Talus Spacer Post Approval Study.

详细描述

This is a Humanitarian Device Exemption (HDE) approved device called the Patient Specific Talus Spacer. This is a post approval study to determine the safety and probable benefit of the Patient Specific Talus Spacer in commercial use. The Patient Specific Talus Spacer is a solid polished replica of the patient's bone to allow the patient to regain motion and reduce pain.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject plans to undergo implantation of the Patient Specific Talus Spacer for avascular necrosis of the ankle joint independent of this research protocol;
  • Avascular necrosis of the ankle joint;
  • Age 21 years old or older;
  • Subject has good general health; and
  • Subject signs a written informed consent form (ICF) prior to the surgical procedure.

排除标准

  • Presence of any contraindication identified in the device Instructions for Use;
  • Surgeon determines that the patient is not appropriate for the Talus Spacer procedure based on the device IFU (including the enumerated Warnings and Precautions);
  • Based on the medical opinion of the surgeon, the patient is not appropriate for the Talus Spacer procedure;
  • For female subjects, pregnancy;
  • Active systemic disease, such as AIDS, HIV, or active infection;
  • Active infection or the skin is compromised at the surgical site; and
  • Systemic disease that would affect the subject's welfare;
  • Is a prisoner, incarcerated, or has been coerced to participate in the study that could impact the validity of results;
  • Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the time course of follow-up.
  • If the Sponsor has notified the site that 30 subjects have been enrolled in the study with a Cobalt Chromium Patient Specific Talus Spacer, and the surgeon believes that a Cobalt Chromium Patient Specific Talus Spacer is the best option for the patient.
  • If the Sponsor has notified the site that 30 subjects have been enrolled in the study with a Titanium (Ti6Al4V) with Titanium Nitride (TiN) coating Patient Specific Talus Spacer, and the surgeon believes that a Titanium (Ti6Al4V) with Titanium Nitride (TiN) coating Patient Specific Talus Spacer is the best option for the patient.

结局指标

主要结局

A lack Secondary Subsequent Surgical Intervention at 5 years Post Operative assessed during the subject's visits

时间窗: A patient will achieve the primary probable benefit endpoint only is they do not undergo a Secondary Subsequent Surgical Intervention at 5 years Post Operative as assessed during the subjects visits for the study.

A lack Secondary Subsequent Surgical Intervention (SSSI) at 5 years Post Operative

Clinically Significant Improvement in Pain on the Visual Analog Scale (VAS)

时间窗: At 5 years compared to Baseline

Clinically Significant Improvement in Pain on the Visual Analog Scale (VAS) at 5 years compared to baseline on the 0 to 100mm scale. A lower score will indicate an improvement in pain.

次要结局

  • Additional Analyses at 5 years Post Operative compared to baseline, Range of Motion of the Ankle.(5 Years Post Procedure compared to baseline.)

研究者

发起方
Paragon 28
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验